C-Peptide (57-87), human

C-Peptide (57-87), human is a synthetic research peptide in the insulin C-peptide family. The listed sequence/design is Glu-Ala-Glu-Asp-Leu-Gln-Val-Gly-Gln-Val-Glu-Leu-Gly-Gly-Gly-Pro-Gly-Ala-Gly-Ser-Leu-Gln-Pro-Leu-Ala-Leu-Glu-Gly-Ser-Leu-Gln. Insulin C-peptide is released during proinsulin processing and is used in studies of insulin biosynthesis, peptide structure, cell signaling, renal physiology, and peptide self-assembly.

• receptor or binding assays
• competition experiments
• enzymatic-processing studies
• antibody or antigen controls
• analytical method development
• LC-MS/HPLC reference work
• comparative structure-activity experiments

Because this product may be a fragment, substituted analog, stereochemical variant, or terminally modified form, its activity should not be assumed to be identical to the native parent peptide. Peptide solubility, aggregation, adsorption to surfaces, and stability can vary with sequence, concentration, pH, ionic strength, and terminal modifications, so assay-specific reconstitution and storage conditions should be validated experimentally.

1. Effects of C-peptide on renal function in experimental diabetes (PMID 9734600).
2. Aggregation propensity of human insulin C-peptide (PMID 27257781).